Blood Journals Portfolio
Jun 21, 2026, 16:12
Cost Savings and Reduced Factor Consumption With Efanesoctocog Alfa – Blood Journals Portfolio
Blood Journals Portfolio shared a post on X about a recent article by Janice M. Staber et al, adding:
”The high-sustained FVIII therapy efanesoctocog alfa resulted in 3 to 5.5 times lower consumption and may save USD 38 947 to USD 81 000 per surgery.
Read the full study in Blood VTH.”
Title: Cost comparison of efanesoctocog alfa vs conventional factor VIII therapies for major surgeries in patients with severe hemophilia A
Authors: Janice M. Staber, Alix Arnaud, Ion Agirrezabal, Duygu Bozkaya, Lane Anson, Andrew Wilson, Nana Kragh, Doris Quon, Allison P. Wheeler
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 21, 2026, 16:21Early Gains in Stroke Knowledge With Stroke Riskometer – International Journal of Stroke
-
Jun 21, 2026, 15:59John Jaksich: Heparin and Anticoagulants – Chemistry, Biotechnology, and Manufacturing
-
Jun 21, 2026, 15:11Mishal Khan: Long-Term Mortality Trends and Demographic Disparities in Patients With PE and AF
-
Jun 21, 2026, 14:57Vimal Koshy Thomas: Adding to the Evidence Base for Endovascular Therapy Beyond 24 Hours
-
Jun 21, 2026, 14:57Abdul Mannan: Integrating Female Reproductive Health into Lifelong Haematology Care
-
Jun 21, 2026, 14:56Ayoub Ait Lahcen: Can We Reduce Blood Transfusions in Cardiac Surgery Before the Operation Even Begins?
-
Jun 21, 2026, 14:38Christina (Tina) P: Staying Safe on Anticoagulation Therapy in Antiphospholipid Syndrome
-
Jun 21, 2026, 14:32Moeen Hoseini: The Sex-Specific Associations Between Inflammatory Biomarkers and Vascular Events
-
Jun 21, 2026, 14:23Orton Lungu: Navigating High-Risk Pregnancy in Women Living With Sickle Cell Disease